002900 Harbin Medisan Pharmaceutical
- 9.85
- +0.85+9.44%
Harbin Medisan Pharmaceutical News
Kazakh Sanlian: Legal Opinion of Beijing Zhonglun Law Firm on the 2022 Restricted Stock Incentive Plan of Harbin Sanlian Pharmaceutical Co., Ltd. on the achievements of lifting sales restrictions during the second period of lifting restrictions, adjustment of repurchase prices, and matters relating to the repurchase and cancellation of some restricted stocks
Kazakh Sanlian: Independent Financial Advisory Report of Shanghai Rongzheng Enterprise Consulting Service (Group) Co., Ltd. on matters relating to the achievements of the 2022 Restricted Stock Incentive Plan of Harbin Sanlian Pharmaceutical Co., Ltd., the results of lifting sales restrictions and the repurchase and cancellation of some restricted stocks
Kazakh Sanlian: Announcement on Adjusting the Repurchase Price of the 2022 Restricted Stock Incentive Plan
Kazakh Triptych: Announcement on the achievements of the 2022 Restricted Stock Incentive Plan to lift the sales restrictions during the second period of lifting the sales restriction period
Kazakh Triptych: Supervisory Board\'s Review Opinions on the 2022 Restricted Stock Incentive Plan\'s Second Lifted Period to Lift the Sales Restriction Incentive List
Kazakh Sanlian: Announcement on the Repurchase and Cancellation of Some Restricted Shares in the 2022 Restricted Stock Incentive Plan
Harbin Medisan Pharmaceutical: Announcement Regarding Extension and Supplementary Pledge of Partial Shares by the Company's Controlling Shareholders and Actual Controllers.
Harbin Medisan Pharmaceutical: 2023 Annual Equity Distribution Implementation Notice
Harbin Medisan Pharmaceutical: Announcement on the 2023 Profit Distribution Plan
Kazakh Sanlian: Announcement on the completion of the repurchase and cancellation of some restricted shares and changes in shares
Kazakhstan Sanlian: An indicative announcement on the 2022 Restricted Stock Incentive Plan\'s first lifting of sales restrictions and lifting the listing and circulation of restricted shares
Kazakhstan Sanlian: Announcement on the achievements of the 2022 Restricted Stock Incentive Plan\'s first lifting of sales restrictions and lifting of sales restrictions conditions
Harbin Sanlian: Shanghai Rongzheng Enterprise Consulting Services (Group) Co., Ltd.\'s independent financial report on the 2022 restricted stock incentive plan of Harbin Sanlian Pharmaceutical Co., Ltd. on the achievements of the first lifting of sales res
Kazakhstan Sanlian: Notice on Adjusting the Repurchase Price of the 2022 Restricted Stock Incentive Plan
Harbin Sanlian: Legal Opinion of Beijing Zhonglun Law Firm on Harbin Sanlian Pharmaceutical Co., Ltd.\'s 2022 Restricted Stock Incentive Plan on matters relating to the first lifting of sales restrictions period and lifting of sales restrictions conditions
Kazakhstan Sanlian: Audit opinion of the Board of Supervisors on the first lifting period of the 2022 Restricted Stock Incentive Plan and the list of sales restriction incentive recipients who can lift sales restrictions
Kazakhstan Sanlian: Announcement on the repurchase and cancellation of some restricted stocks in the 2022 Restricted Stock Incentive Plan
Kazakh Sanlian: Announcement on the cancellation of pledge, rollover, supplementary pledge and re-pledge of some shares of the company\'s controlling shareholders and actual controllers
Kazakh Triptych: 2022 Annual Equity Distribution Implementation Notice
Kazakh Sanlian: Announcement on the completion of the cancellation of share repurchases and changes in shares
Analysis
Price Target
No Data
No Data